Stock-based compensation (Tables)
|
6 Months Ended |
Sep. 30, 2026 |
|---|
| Share-Based Payment Arrangement [Abstract] |
|
| Schedule of stock-based compensation expense |
Stock-based compensation expense was classified in the consolidated statements of operations as follows: | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended
September 30, | | Six Months Ended
September 30, | | 2026 | | 2025 | | 2026 | | 2025 | | Research and development | $ | 4,854 | | | $ | 4,379 | | | $ | 8,461 | | | $ | 9,068 | | | Selling, general and administrative | 5,691 | | | 3,959 | | | 9,758 | | | 8,032 | | | $ | 10,545 | | | $ | 8,338 | | | $ | 18,219 | | | $ | 17,100 | |
The following table summarizes stock-based compensation expense by award type for the three and six months ended September 30, 2026 and 2025: | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended
September 30, | | Six Months Ended September 30, | | 2026 | | 2025 | | 2026 | | 2025 | | Stock options | $ | 3,363 | | | $ | 4,161 | | | $ | 6,823 | | | $ | 8,298 | | Restricted and performance stock units | 7,182 | | | 4,177 | | | 11,396 | | | 8,802 | | | $ | 10,545 | | | $ | 8,338 | | | $ | 18,219 | | | $ | 17,100 | |
|
| Schedule of assumptions used to determine the grant-date fair value of stock options granted |
The following table presents, on a weighted-average basis, the assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and directors: | | | | | | | | | | | | | | | | | | | | | | Three Months Ended
September 30, | Six Months Ended
September 30, | | 2026 | | 2025 | 2026 | | 2025 | | Risk-free interest rate | 4.61 | % | | 4.00 | % | 4.12 | % | | 3.97 | % | | Expected term (in years) | 6.1 | | 6.1 | 6.0 | | 6.0 | | Expected volatility | 124.1 | % | | 83.9 | % | 109.0 | % | | 76.5 | % | | Expected dividend yield | 0 | % | | 0 | % | 0 | % | | 0 | % |
|
| Schedule of of stock option activity |
The following table summarizes the Company’s stock option activity: | | | | | | | | | | | | | | | | | | | | | | | | | Number of
Shares | | Weighted
Average
Exercise
Price | | Weighted
Average
Contractual
Term (Years) | | Aggregate
Intrinsic
Value | | Outstanding as of March 31, 2026 | 11,785,458 | | | $ | 14.12 | | | 5.63 | | $ | 4,323 | | | Granted | 2,444,528 | | | 8.41 | | | | | | | Exercised | (770,895) | | | 7.48 | | | | | | | Cancelled | (2,185,558) | | | 16.58 | | | | | | | Outstanding as of September 30, 2026 | 11,273,533 | | | 12.86 | | | 5.89 | | 36,823 | | | Options exercisable as of September 30, 2026 | 7,523,534 | | | 14.82 | | | 4.40 | | 19,464 | | | Options vested and expected to vest as of September 30, 2026 | 11,273,533 | | | $ | 12.86 | | | 5.89 | | $ | 36,823 | |
|
| Schedule of share-based payment arrangement, restricted stock and restricted stock unit, activity |
A summary of the changes in the Company’s RSUs and PSUs during the six months ended September 30, 2026 is as follows: | | | | | | | | | | | | | Number of Restricted Shares | | Weighted
Average
Grant Date Fair Value | | Outstanding as of March 31, 2026 | 5,508,882 | | | $ | 9.69 | | | Granted | 3,284,980 | | | 9.05 | | | Vested | (1,615,846) | | | 9.93 | | | Cancelled | (2,231,032) | | | 8.79 | | | Outstanding as of September 30, 2026 | 4,946,984 | | | $ | 9.59 | |
|